95700-16-6

Basic information

• Product Name: Z-GLN-OBZL
• Synonyms: N-ALPHA-CARBOBENZOXY-L-GLUTAMINE ALPHA-BENZYL ESTER;Z-GLN-OBZL;Z-L-GLUTAMINE BENZYL ESTER
• CAS NO: 95700-16-6
• Molecular Formula: C₂₀H₂₂N₂O₅
• Molecular Weight: 370.4
• Mol File: 95700-16-6.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Z-GLN-OBZL(CAS DataBase Reference)
• NIST Chemistry Reference: Z-GLN-OBZL(95700-16-6)
• EPA Substance Registry System: Z-GLN-OBZL(95700-16-6)

Safety Data

• Hazardous Substances Data: 95700-16-6(Hazardous Substances Data)

Upstream product

• 60-29-7 diethyl ether 
• 10026-13-8 phosphorus pentachloride 
• 3705-42-8 Cbz-(L)-Glu-OBn 
• 100-51-6 benzyl alcohol 
• 4124-76-9 N-(benzyloxycarbonyl)-L-glutamic acid anhydride 
• 96671-01-1 Carbobenzoxy-L-glutaminsaeure-α-benzylester-γ-thiophenylester 
• 5281-18-5 benzaldehyde, hydrazone 
• 2650-64-8 Cbz-L-Gln 
• 100-52-7 benzaldehyde 

Downstream Products

• 124921-76-2 (2S)-4-Amino-2-(benzyloxycarbonylamino)butansaeure-benzylester 
• 1430197-58-2 N^δ-(5-tert-butyl-diphenylsilyl-2,3-di-O-benzyl-α-D-ribosyl)-N^α-benzyloxycarbonylglutamine benzyl ester 
• 1430197-66-2 N^δ-(5-triisopropylsilyl-2,3-di-O-(4-methoxybenzyl)-α-D-ribosyl)-N^α-benzyloxycarbonylglutamine benzyl ester 
• 1430197-88-8 N^δ-(5-triisopropylsilyl-2,3-di-O-(4-methoxybenzyl)-β-D-ribosyl)-N^α-benzyloxycarbonylglutamine benzyl ester 
• 1430197-49-1 N^δ-(2,3,5-tri-O-benzyl-α-D-ribosyl)-N^α-benzyloxycarbonylglutamine benzyl ester 
• 1430197-80-0 N^δ-(2,3,5-tri-O-benzyl-β-D-ribosyl)-N^α-benzyloxycarbonylglutamine benzyl ester 
• 1430197-59-3 N^δ-(5-triisopropylsilyl-2,3-di-O-benzyl-α-D-ribosyl)-N^α-benzyloxycarbonylglutamine benzyl ester 
• 1240045-91-3 Z-Gln(Pmbf)-OBzl 
• 888937-70-0 -benzylester 
• 903502-23-8 (S)-2-benzyloxycarbonylamino-4-[(1S,2R)-2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethylcarbamoyl]butyric acid benzyl ester 

Relevant articles and documents

A Novel compound

The present invention relates to a novel compound and uses thereof. The novel compound according to the present invention, by inducing the activation of an MKP-1 protein, has an effect of inhibiting inflammatory responses very effectively that occur in respiratory diseases by blocking cell signaling in the order of p38/CK2alpha/NF-kappaB. Accordingly, it is possible to prevent, alleviate or treat the respiratory diseases by oral administration of the novel compound of the present invention.